Phase 4
N=31
Ranolazine and Microvascular Angina by PET in the Emergency Department
Microvascular Angina
Bottom Line
View on ClinicalTrials.gov: NCT02052011 ↗Enrolled (actual)
31
Serious AEs
0.0%
Results posted
May 2017
Primary outcome: Primary: Coronary Flow Reserve — 1.6; 1.6; 1.9; 1.6 ratio
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Ranolazine (Drug); Placebo (Drug)
- Age
- Adult, Older Adult · 30+ yrs
- Sex
- All
- Sponsor
- Yale University
- Primary completion
- Nov 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Coronary Flow Reserve |
1.6; 1.6; 1.9; 1.6 | — |
Summary
The purpose of this study is to determine the effectiveness of Ranolazine for the treatment chest pain from disease of small vessels of the heart also known as 'microvascular angina'.
Eligibility Criteria
Inclusion Criteria
- Patients admitted to the Yale ED CPC
- ≥ 30 years age
- chest pain or angina equivalent as their chief complaint within 24 hours of enrollment
- Coronary Flow Reserve(CFR) 10 on PET scan)
- Resting blood pressure of systolic >180/110 mm Hg or 580 msec
- use of drugs that prolong QTc (Haldol, erythromycin)
- pregnancy
- inability to read or understand English
- suffering from a condition that precludes interview (i.e. cognitive or communication impairment).
Data sourced from ClinicalTrials.gov (NCT02052011). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.